Company Overview of Celyad SA
Celyad SA, a clinical-stage biopharmaceutical company, focuses on engineered cell therapy treatments. It develops therapeutic therapies for the treatment of unmet medical needs in cardiology and oncology. The company offers C-Cure, an autologous cell therapy for the treatment of heart failure. It also provides NKR-2, an autologous chimeric antigen receptor (CAR), a lab engineered receptor for the treatment of cancer. In addition, the company’s pre-clinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection catheter; heart access sheath...
Rue Edouard Belin 12
Founded in 2004
Key Executives for Celyad SA
Chief Executive Officer and Executive Director
Total Annual Compensation: €579.0K
Compensation as of Fiscal Year 2015.
Celyad SA Key Developments
Celyad S.A. Successfully Completes Safety Follow-Up of the First Patient at the Fourth Dose Level in the NKR-2 Phase I Trial
Jul 14 16
Celyad S.A. announced the successful completion of the 21-day safety follow-up of the first patient enrolled at the fourth dose level in its Phase I/IIa clinical trial evaluating the safety and feasibility of its NKR-2 T-cell therapy using T-cells engineered to express the NKG2D receptor in Acute Myeloid Leukemia and Multiple Myeloma patients. No safety issues or toxicities were reported. The next patient of the cohort has already been infused.
ONO PHARMACEUTICAL CO Enters into License Agreement with Celyad for its Allogeneic Car T-Cell Therapy (NKR-2)
Jul 11 16
ONO PHARMACEUTICAL CO., LTD. announced that it has entered into an exclusive license agreement with Celyad to develop and commercialize Celyad's NKG2D-ligand targeting allogeneic CAR T-cell therapy, NKR-2, in Japan, South Korea and Taiwan. ONO will pay to Celyad an upfront payment of JPY 1.25 billion at closing of the agreement and a maximum total of JPY 30.075 billion thereafter milestone payments based on development stage as well as upon the achievement of specified net sales threshold. The agreement also calls for double digit royalties on net sales in ONO's territories. Under the terms of the agreement, ONO will be responsible for future development and commercialization in its territories. Celyad retains all the right of allogeneic NKR-2 in the rest of the world. Both companies will also explore the opportunity to collaborate to run global registration trials and combination trials. In addition, Celyad grants to ONO an exclusive option to license for development and commercialization of its autologous NKR-2 in the above ONO's territories.
Celyad SA - Special Call
Jul 11 16
To review the licensing agreement with ONO Pharmaceutical
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries